Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
2008 1
2010 1
2011 1
2012 1
2013 2
2014 1
2016 1
2017 2
2019 1
2020 1
2021 2
2022 4
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Acute kidney injury in patients treated with immune checkpoint inhibitors.
Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, Ostermann M, Herrmann SM, Abudayyeh A, Anand S, Glezerman I, Motwani SS, Murakami N, Wanchoo R, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, Seigneux S, Campedel L, Kitchlu A, Shin DS, Rangarajan S, Deshpande P, Coppock G, Eijgelsheim M, Seethapathy H, Lee MD, Strohbehn IA, Owen DH, Husain M, Garcia-Carro C, Bermejo S, Lumlertgul N, Seylanova N, Flanders L, Isik B, Mamlouk O, Lin JS, Garcia P, Kaghazchi A, Khanin Y, Kansal SK, Wauters E, Chandra S, Schmidt-Ott KM, Hsu RK, Tio MC, Sarvode Mothi S, Singh H, Schrag D, Jhaveri KD, Reynolds KL, Cortazar FB, Leaf DE; ICPi-AKI Consortium Investigators. Gupta S, et al. J Immunother Cancer. 2021 Oct;9(10):e003467. doi: 10.1136/jitc-2021-003467. J Immunother Cancer. 2021. PMID: 34625513 Free PMC article.
Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer.
Gupta S, Strohbehn IA, Wang Q, Hanna PE, Seethapathy R, Prosek JM, Herrmann SM, Abudayyeh A, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, de Seigneux S, Campedel L, Kitchlu A, Shin DS, Coppock G, Lumlertgul N, Garcia P, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Benesova K, Jhaveri KD, Cortazar FB, Weins A, Zuo Y, Mooradian MJ, Reynolds KL, Leaf DE, Sise ME; ICPi-AKI Consortium. Gupta S, et al. Kidney Int. 2022 Oct;102(4):930-935. doi: 10.1016/j.kint.2022.07.019. Epub 2022 Aug 11. Kidney Int. 2022. PMID: 35964800 Free PMC article. No abstract available.
Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI.
Gupta S, Garcia-Carro C, Prosek JM, Glezerman I, Herrmann SM, Garcia P, Abudayyeh A, Lumlertgul N, Malik AB, Loew S, Beckerman P, Renaghan AD, Carlos CA, Rashidi A, Mithani Z, Deshpande P, Rangarajan S, Shah CV, Seigneux S, Campedel L, Kitchlu A, Shin DS, Coppock G, Ortiz-Melo DI, Sprangers B, Aggarwal V, Benesova K, Wanchoo R, Murakami N, Cortazar FB, Reynolds KL, Sise ME, Soler MJ, Leaf DE; ICPi-AKI Consortium Investigators. Gupta S, et al. J Immunother Cancer. 2022 Sep;10(9):e005646. doi: 10.1136/jitc-2022-005646. J Immunother Cancer. 2022. PMID: 36137651 Free PMC article.
Pancreatic cancer heterogeneity and response to Mek inhibition.
Pedersen K, Bilal F, Bernadó Morales C, Salcedo MT, Macarulla T, Massó-Vallés D, Mohan V, Vivancos A, Carreras MJ, Serres X, Abu-Suboh M, Balsells J, Allende E, Sagi I, Soucek L, Tabernero J, Arribas J. Pedersen K, et al. Among authors: carreras mj. Oncogene. 2017 Oct 5;36(40):5639-5647. doi: 10.1038/onc.2017.174. Epub 2017 Jun 5. Oncogene. 2017. PMID: 28581516
The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening Rate.
Aceituno L, Bañares J, Ruiz-Ortega L, Callejo-Pérez A, Muñoz-Couselo E, Ortiz-Velez C, Díaz-Mejía N, Barreira-Díaz A, Carreras MJ, Farriols A, Buti M, Riveiro-Barciela M. Aceituno L, et al. Among authors: carreras mj. Front Med (Lausanne). 2022 Jul 15;9:916213. doi: 10.3389/fmed.2022.916213. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35911389 Free PMC article.
Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center.
Carpio C, Iacoboni G, Villacampa G, Catalá E, Bobillo S, Pérez A, Jiménez M, Segura L, Olivé M, Farriols A, Abrisqueta P, Valcárcel D, Carreras MJ, Bosch F, Barba P. Carpio C, et al. Among authors: carreras mj. Leuk Lymphoma. 2021 Sep;62(9):2288-2291. doi: 10.1080/10428194.2021.1913141. Epub 2021 Apr 24. Leuk Lymphoma. 2021. PMID: 33899648 No abstract available.
21 results